A clinical evaluation of patients with known mutations (plasminogen and factor XII) with a focus on prophylactic treatment
Background Hereditary angioedema with normal C1-inhibitor (HAE-nC1-INH) is a rare genetic disease. The symptoms can resemble other forms of hereditary angioedema (HAE), but the specific laboratory values are inconspicuous. The knowledge about treatment strategies in HAE-nC1-INH remains insufficient;...
Saved in:
| Main Authors: | Robin Lochbaum, Susanne Trainotti, Thomas K. Hoffmann, Jens Greve, Janina Hahn |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Journal of Dermatological Treatment |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/09546634.2023.2290362 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Real-world evidence of the effectiveness and utilization of subcutaneous C1INH long-term prophylaxis in patients with HAE in Spain and Germany
by: Marcus Maurer, et al.
Published: (2025-05-01) -
A COSMIN systematic review of instruments for evaluating health-related quality of life in people with Hereditary Angioedema
by: Irene Baroni, et al.
Published: (2025-02-01) -
Real-World Outcomes and Healthcare Utilization of Lanadelumab in Spain: Insights from First Cohort of Difficult-to-Treat Hereditary Angioedema Cases
by: Inmaculada Sánchez-Machín, et al.
Published: (2025-02-01) -
Global frequency, diagnosis, and treatment of hereditary angioedema with normal C1 inhibitor
by: Markus Magerl, MD, et al.
Published: (2025-08-01) -
Unveiling the Complexities of Hereditary Angioedema
by: Cristina Violeta Tutunaru, et al.
Published: (2024-10-01)